Starting with insulin over six decades ago, biologics have become the fastest-growing class of therapeutic compounds. They have provided treatment options for people who suffer from some of the most serious medical conditions, such as rheumatoid arthritis, cancer, rare blood disorders, multiple sclerosis, diabetes and HIV/AIDS. Thanks to biologics, these patients can now be treated; whereas no effective therapies were previously available. About 300 biologics are now available for human use, and account for over $200 Million in global sales in 2016.
The holiday season is upon us once again! It’s a happy and exciting period for some, but can also be a stressful and borderline anxiety-inducing time for others.
Dinners, parties, spending your last three paychecks on gifts, gifts and more gifts … Don’t let this long list of to-dos and over-the-top expectations overwhelm you and turn this joyful season into a treacherous one.
Follow our 7 easy tips to check the holiday drama at the door and get through the next few weeks without spiking your blood pressure:
Welcome to a “This Day in History” edition of our blog! Every evening, since I was just a kid, I have tuned in to watch Jeopardy on TV. Maybe it’s because I’m a big geek… or maybe I just like to torture myself since trivia has never been my forte. Today, I woke up feeling dedicated to learning something new… random facts that may one day help me “make it a true daily double”.
So here it goes…
According to Verified Clinical Trials (VCT), a worldwide clinical trials database registry to prevent dual enrollment in clinical trials, the incidence of dual enrollment per trial is 2%-10% depending on the therapeutic area and phase of the study. For Phase I units, VCT reports that up to 25% of clinical research volunteers attempt multiple simultaneous clinical trial enrollment.
It’s the much-anticipated Part II of our “What Does it Take” series (insert glorious trumpet announcement sound here). In Part I, we discussed general First-In-Human (FIH) clinical trials, and today we’re going to go a step further to discuss biologic and biosimilar FIH trials.
Biologic vs. Biosimilar
It’s important, for those who are unfamiliar, to first understand how the FDA views biologics and biosimilars for the purposes of drug development.
Does the CRO you’re working with have what it takes to successfully conduct First-in-Human (FIH) clinical research?
In a few short weeks we, along with Cambridge Cognition, will be hosting a symposium in Boston on the early phase development of centrally-acting drugs (you can still register to attend if you haven’t done it already!), so we thought it fitting to do a blog highlighting the biotech hub there.
Our bodies are about two-thirds water. That H20 is responsible for regulating temperature, lubricating joints, protecting the spinal cord, and removing toxins and waste from the body. When it’s hot outside (and feels like the fires of Hades are licking the skin off your body) it’s even more important to make sure you’re making water a priority in your daily routine.
Last week we talked about our awesome lab staff who are responsible for sample collection and processing during a clinical trial. This week, we’re highlighting our expert bioanalytical scientific team!
At the Altasciences facility in Laval, Quebec, we have more than 100 dedicated bioanalytical scientists who work in our 20,000-sq.-ft. laboratory with the latest equipment to support all phases of clinical development (Preclinical through Phase I-IV).